Generic Krazati Availability

Last updated on Jun 11, 2025.

Krazati is a brand name of adagrasib, approved by the FDA in the following formulation(s):

KRAZATI (adagrasib - tablet;oral)

• Manufacturer: BRISTOL
  Approval date: December 12, 2022
  Strength(s): 200MG ^[RLD]

Is there a generic version of Krazati available?

No. There is currently no therapeutically equivalent version of Krazati available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Krazati. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• KRas G12C inhibitors
  Patent 10,689,377
  Issued: June 23, 2020
  Inventor(s): Blake; James F. et al.
  Assignee(s): Mirati Therapeutics, Inc. (San Diego, CA); Array Biopharma Inc. (Boulder, CO)
  

  The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

  Patent expiration dates:

  • May 17, 2037
    
    ✓ 
    Patent use: TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  • May 17, 2037
    
    ✓ 
    Patent use: TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Crystalline forms of a KRas G12C inhibitor
  Patent 12,281,113
  Issued: April 22, 2025
  Inventor(s): Andres; Patricia et al.
  Assignee(s): MIRATI THERAPEUTICS, INC. (Princeton, NJ)
  

  The present invention relates to crystalline forms of a KRas G12C inhibitor and salt thereof. In particular, the present invention relates to crystalline forms of the KRas G12C inhibitor 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, pharmaceutical compositions comprising the crystalline forms, processes for preparing the crystalline forms and methods of use thereof.

  Patent expiration dates:

  • September 10, 2041
    
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • December 12, 2027 - NEW CHEMICAL ENTITY
  • December 12, 2029 - TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer